SEC Filing Summary: Nuvilex, Inc. (Form 10-K)
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended April 30, 2011, for Nuvilex, Inc. (formerly DJH International, Inc. and eFoodSafety.com, Inc.). The Company is a smaller reporting company incorporated in Nevada, trading on the OTCQB under the symbol "NVLX." Nuvilex operates as an early-stage biotechnology and consumer products firm, manufacturing and marketing nutritional supplements (Cinnergen, Cinnechol), scar creams (Talsyn), tattoo inks (Infinitink), and germicidal products (Citroxin). The Company has undergone significant strategic pivots since its inception in 1996, moving from food safety to health and wellness products.
Key Financial Metrics
| Metric | Fiscal 2011 | Fiscal 2010 |
|---|---|---|
| Total Revenue | $125,997 | $262,932 |
| Gross Profit | $93,893 | $34,273 |
| Net Loss | $(1,397,716) | $(5,991,925) |
| Operating Expenses | $482,254 | $5,650,857 |
| Cash and Equivalents (End of Period) | $57,201 | $716 |
| Total Assets | $1,240,187 | $1,202,217 |
| Total Liabilities | $3,389,480 | $3,153,362 |
| Working Capital | $(3,284,733) | $(3,039,683) |
| Accumulated Deficit | $(37,948,693) | $(36,550,977) |
Note: Fiscal 2010 included a non-cash impairment charge of $3.5 million related to the acquisition of Freedom-2 Holdings, Inc.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 52% from $262,932 in 2010 to $125,997 in 2011. Product sales dropped significantly ($262,932 to $75,997) due to a lack of product liability insurance for most of the year, though $50,000 in royalty revenue was recognized in 2011.
- Expense Reduction: Operating expenses plummeted from $5.65 million in 2010 to $482,254 in 2011. This reduction was driven primarily by the absence of the $3.5 million goodwill impairment charge recorded in the prior year and aggressive cuts to Sales & Marketing ($411k to $11k) and R&D ($492k to $9k).
- Net Loss Improvement: While the Company remains unprofitable, the net loss narrowed significantly to $1.4 million in 2011 compared to $6.0 million in 2010, largely due to the one-time impairment charge in the prior period.
- Liquidity Position: Cash on hand increased from $716 to $57,201, funded by $100,000 in stock sales and $117,429 in related party borrowings. However, negative working capital widened slightly.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The Company's independent auditors have issued a "going concern" opinion. Nuvilex has not established an ongoing source of revenue sufficient to cover operating costs. The Company relies on additional funding from Dr. Ryan and other investors to continue operations. Management's strategy focuses on reducing cash burn, selling or leasing the Freedom-2 property, and executing revenue growth plans.
Legal Proceedings: In July 2011, Cornerstone Bank filed a claim against subsidiary Freedom-2, Inc., seeking foreclosure on a property in Cherry Hill, NJ, and enforcement of a pledge of 14.6 million shares of Nuvilex common stock. The Company estimates a potential loss between $750,000 and $1,000,000, with a worst-case scenario of 100% liability plus fees. A stock payable and expense of $730,281 has been recorded regarding the pledged shares.
Internal Controls: Management concluded that disclosure controls and procedures were not effective as of April 30, 2011. Material weaknesses include a lack of a disseminated code of ethics, undeveloped accounting policies, and no Audit Committee financial expert on the Board.
Outlook: The Company anticipates continued financial difficulties. Future success depends on raising capital, resolving debt issues, and achieving market penetration for products like Infinitink and Cinnergen. There is no assurance that additional financing will be available.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure immediate capital to cover the $3.39 million in current liabilities and negative working capital.
- Legal Exposure: Confirm the status of the Cornerstone Bank foreclosure and the potential dilution or loss of 14.6 million shares pledged as collateral.
- Revenue Sustainability: Assess the viability of the $50,000 royalty revenue stream from purEffect, noting that the partner (CK41) is currently delinquent on payments.
- Internal Controls: Review the Company's progress in remedying material weaknesses in financial reporting and the appointment of an Audit Committee financial expert.
- Asset Valuation: Investigate the status of the "Asset held for sale" (Cherry Hill property) valued at $1.081 million and the likelihood of a successful sale to resolve debt.